BIOXXMED AG Capital issue provides the DermaTools Biotech GmbH with about 1.3 million EUR
fresh capital
Resources will be used to prepare further clinical trials and the clinical trials in the USA
Federal State of Hessen participates in the capital increase through Hessen-Kapital
Darmstadt, 17th June 2015 - within the scope of a capital increase, the shareholders` general meeting of the DermaTools Biotech GmbH acquired about 1.3 million EUR from the existing shareholders and the State of Hessen. The decision was submitted to the commercial register. The CytoTools AG participates within the framework of its financial possibilities keeping its proportionate holding in the DermaTools Biotech GmbH almost constant. With the comprehensive strengthening of liquidity, the CytoTools AG, and all the other existing shareholders, support the ongoing trials of DermaTools in Europe and also provide the means to continue the trial preparations for the ulcus cruris indication in the USA, and for the initiation of further clinical trials.
"The positive meetings with the FDA in the USA in April have strengthened our resolve to pursue the preparations for clinical trials for the ulcus cruris indication. The extension of the clinical trials for the active substance DermaPro® will be financed with the newly acquired means. Here, there are further great potentials for the innovative patented active substance molecule." said Dr. Dirk Kaiser, board member and Chief Research Officer of CytoTools AG.
"As well as the increased possibilities in the field of research and development, we also see this as a great expression of confidence by the existing shareholders, because thi s round of financing enables DermaTools to start further projects. We are particularly pleased that the State of Hessen is also investing further in the future industry biotechnology, creating an excellent starting base for establishing more technological companies", concluded Dr. Mark-Andre Freyberg, board member and CEO of the CytoTools AG.
This press release contains specific future-oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future- oriented statements made. CytoTools is not obligated to update these future-oriented statements.
PRESS INFORMATIONAbout CytoTools:
CytoTools AG is a German biotechnology company focused on translating fundamental biology research on the mechanisms of cell growth and programmed cell death into unique therapies that are designed to treat the cause of the disease rather than the symptoms. The Company has developed a robust and diverse pipeline of disease modifying therapies that comprise proprietary small molecules and biologics. These have the potential to provide new treatment options in dermatology, cardiology and angiology, urology and oncology. CytoTools AG is structured as an investment and holding company and as such holds investments in its subsidiaries DermaTools Biotech GmbH (55%) and CytoPharma GmbH (42%).
Contact:CytoTools AG
Dr. Mark Andre Freyberg
Klappacher Str. 126
D-64285 Darmstadt
Tel.: +49-6151-95158-12
Fax: +49-6151-95158-13
E-Mail: freyberg@cytotools.de
Press and Investor Relations:Instinctif Partners
Dr. Robert Mayer/Ursula Querette
Rindermarkt 5
D-80331 Munich
Tel.: +49-89-3090 5189-13
E-Mail: cytotools@instinctif.com
|
distributed by
|
